Functional Characterization of Full-length BARD1 Strengthens Its Role As a Tumor Suppressor in Neuroblastoma

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Feb 13

PMID 32047556

Citations 12

Authors

Flora Cimmino

Marianna Avitabile

Vito Alessandro Lasorsa

Lucia Pezone

Antonella Cardinale

Annalaura Montella

Sueva Cantalupo

Achille Iolascon

Mario Capasso

Affiliations

Soon will be listed here.

Abstract

is associated with the development of high-risk neuroblastoma patients. Particularly, the expression of full length (FL) isoform, FL , correlates to high-risk neuroblastoma development and its inhibition is sufficient to induce neuroblastoma cells towards a worst phenotype. Here we have investigated the mechanisms of FL in neuroblastoma cell lines depleted for FL expression. We have shown that FL expression protects the cells from spontaneous DNA damage and from damage accumulated after irradiation. We demonstrated a role for FL as tumor suppressor to prevent unscheduled mitotic entry of DNA damaged cells and to lead to death cells that have bypassed cell cycle checkpoints. FL -depleted cells that have survived to checkpoints acquire features of aggressiveness. Overall, our results show that FL may defend cells against cancer and prevent malignant transformation of cells.

Citing Articles

Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation.

Tirelli M, Bonfiglio F, Cantalupo S, Montella A, Avitabile M, Maiorino T Hum Genet. 2024; 143(11):1293-1309.

PMID: 39192051 PMC: 11522082. DOI: 10.1007/s00439-024-02700-2.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

Randall M, Egolf L, Vaksman Z, Samanta M, Tsang M, Groff D J Natl Cancer Inst. 2023; 116(1):138-148.

PMID: 37688570 PMC: 10777668. DOI: 10.1093/jnci/djad182.

germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

Randall M, Egolf L, Vaksman Z, Samanta M, Tsang M, Groff D bioRxiv. 2023; .

PMID: 36778420 PMC: 9915690. DOI: 10.1101/2023.01.31.525066.

Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways.

Avitabile M, Bonfiglio F, Aievola V, Cantalupo S, Maiorino T, Lasorsa V Comput Struct Biotechnol J. 2022; 20:4437-4445.

PMID: 36051886 PMC: 9418686. DOI: 10.1016/j.csbj.2022.08.031.

FGFR1 is a potential therapeutic target in neuroblastoma.

Cimmino F, Montella A, Tirelli M, Avitabile M, Lasorsa V, Visconte F Cancer Cell Int. 2022; 22(1):174.

PMID: 35488346 PMC: 9052553. DOI: 10.1186/s12935-022-02587-x.

References

Longo L, Panza E, Schena F, Seri M, Devoto M, Romeo G . Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. Hum Hered. 2007; 63(3-4):205-11. DOI: 10.1159/000099997. View

Yoshino Y, Qi H, Fujita H, Shirota M, Abe S, Komiyama Y . BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number. Mol Cancer Res. 2018; 16(10):1499-1511. DOI: 10.1158/1541-7786.MCR-18-0269. View

Lasorsa V, Formicola D, Pignataro P, Cimmino F, Calabrese F, Mora J . Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget. 2016; 7(16):21840-52. PMC: 5008327. DOI: 10.18632/oncotarget.8187. View

Bosse K, Diskin S, Cole K, Wood A, Schnepp R, Norris G . Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012; 72(8):2068-78. PMC: 3328617. DOI: 10.1158/0008-5472.CAN-11-3703. View

Westermark U, Reyngold M, Olshen A, Baer R, Jasin M, Moynahan M . BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol. 2003; 23(21):7926-36. PMC: 207645. DOI: 10.1128/MCB.23.21.7926-7936.2003. View

Shaheen M, Allen C, Nickoloff J, Hromas R . Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood. 2011; 117(23):6074-82. DOI: 10.1182/blood-2011-01-313734. View

Wu J, Vlastos A, Pelte M, Caligo M, Bianco A, Krause K . Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int J Cancer. 2005; 118(5):1215-26. DOI: 10.1002/ijc.21428. View

Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine J . Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011; 10(6):983-93. DOI: 10.1158/1535-7163.MCT-10-1090. View

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner J, Attiyeh E . Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009; 41(6):718-23. PMC: 2753610. DOI: 10.1038/ng.374. View

10.

Russell M, Penikis A, Oldridge D, Alvarez-Dominguez J, McDaniel L, Diamond M . CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res. 2015; 75(15):3155-66. PMC: 4526355. DOI: 10.1158/0008-5472.CAN-14-3613. View

11.

Combaret V, Iacono I, Bellini A, Brejon S, Bernard V, Marabelle A . Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 2015; 4(4):540-50. PMC: 4402069. DOI: 10.1002/cam4.414. View

12.

Irminger-Finger I, Ratajska M, Pilyugin M . New concepts on BARD1: Regulator of BRCA pathways and beyond. Int J Biochem Cell Biol. 2016; 72:1-17. DOI: 10.1016/j.biocel.2015.12.008. View

13.

McCarthy E, Celebi J, Baer R, Ludwig T . Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol. 2003; 23(14):5056-63. PMC: 162231. DOI: 10.1128/MCB.23.14.5056-5063.2003. View

14.

Yarden R, Pardo-Reoyo S, Sgagias M, Cowan K, Brody L . BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet. 2002; 30(3):285-9. DOI: 10.1038/ng837. View

15.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

16.

Zhang Y, Bianco A, Malkinson A, Leoni V, Frau G, Rosa N . BARD1: an independent predictor of survival in non-small cell lung cancer. Int J Cancer. 2011; 131(1):83-94. DOI: 10.1002/ijc.26346. View

17.

Cimmino F, Formicola D, Capasso M . Dualistic Role of BARD1 in Cancer. Genes (Basel). 2018; 8(12). PMC: 5748693. DOI: 10.3390/genes8120375. View

18.

Cobrinik D, Ostrovnaya I, Hassimi M, Tickoo S, Cheung I, Cheung N . Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosomes Cancer. 2013; 52(12):1150-66. DOI: 10.1002/gcc.22110. View

19.

Shabbeer S, Omer D, Berneman D, Weitzman O, Alpaugh A, Pietraszkiewicz A . BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. Oncogene. 2012; 32(42):5005-16. PMC: 3796024. DOI: 10.1038/onc.2012.522. View

20.

Sporn J, Hothorn T, Jung B . BARD1 expression predicts outcome in colon cancer. Clin Cancer Res. 2011; 17(16):5451-62. PMC: 3372413. DOI: 10.1158/1078-0432.CCR-11-0263. View